Rare Drug for Treating Alpha-mannosidosis Approved for the First Time in Korea
Ministry of Food and Drug Safety Approves Import of Lamzedeju 10mg
The Ministry of Food and Drug Safety announced on January 12 that it has approved the import of the rare drug "Lamzedeju 10mg" (ingredient name: velmanase alfa), which is used to treat non-central nervous system symptoms in patients with alpha-mannosidosis.
Alpha-mannosidosis is a disorder caused by a deficiency of the lysosomal alpha-mannosidase enzyme, resulting in the accumulation of mannose-containing oligosaccharides that cannot be broken down. This leads to symptoms such as facial and skeletal abnormalities and immunodeficiency.
Lamzedeju is a recombinant human alpha-mannosidase enzyme. It supplements the deficient enzyme in patients with alpha-mannosidosis, thereby reducing the accumulation of mannose-containing oligosaccharides in organs and alleviating non-central nervous system symptoms.
Until now, there has been no approved treatment for patients with alpha-mannosidosis in Korea. However, with this approval, patients are expected to have new treatment opportunities.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Ministry of Food and Drug Safety stated, "We will continue to do our utmost to ensure that new treatments are supplied quickly to patients with rare diseases, expanding their treatment opportunities based on our expertise in regulatory science."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.